Patient characteristics and outcome in our series of seven patients with TC secondary to COVID-19
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | |
| Age | 71 | 78 | 70 | 78 | 88 | 58 | 56 |
| Gender | Female | Male | Female | Female | Male | Male | Male |
| Presentation | Cough, myalgia, lethargy | AMS, fever, urinary incontinence | SOB | Fever, cough, SOB | SOB, lethargy, worsening hypoxia | SOB, DOE | SOB and fever |
| History | DM, HLD, HTN | DM, HLD, HTN, CVA, AF | DM, HTN, HLD | DM, HLD, HTN, CVA, AF | DM, HTN, HLD, CVA, AF, CAD, HFrEF, CRF | HLD | Schizophrenia HTN AF, stroke, HLD |
| Intubation | Yes | Yes | Yes | No | Yes | Yes | Yes |
| PaO2/FiO2 | 64.7 | 242 | 82 | 75 | 279 | 138 | 124 |
| Vasopressors | Yes | Yes | Yes | No | Yes | Yes | Yes |
| Peak leucocyte count (x103/μL) (reference 4.5–11.0) | 12.1 | 11.1 | 15.5 | 13.5 | 28.1 | 28 | 10.5 |
| Troponin (ng/mL) (reference <0.03) | 3.77 | 0.3 | <0.01 | 0.03 | 0.2 | 0.22 | 0.12 |
| CPK (U/L) (reference 39–397) | – | 1128 | 301 | 351 | 43 | 135 | 1959 |
| NT-pro-BNP (pg/mL) (reference 0–900) | 954 | 1674 | 788 | 42 837 | 46 568 | 86 | 1226 |
| CRP (mg/dL) (reference <0.5) | 26.1 | 23.44 | 26.70 | 28.10 | 1.30 | 18.43 | 6 |
| Ferritin (ng/mL) (reference 30–400) | – | 2787 | 258 | 9445 | 1926 | 684 352 | 4809 |
| D-Dimer quant (μg/mL FEU) (reference <0.5) | 2.95 | 4.06 | 16.28 | >20 | 2 | >20 | 10.27 |
| LDH (U/L) (reference 102–266) | 497 | 945 | 328 | 1224 | 344 | 11 403 | 356 |
| ECG changes | Atrial flutter RVR with diffuse ST elevations (figure 3) | AF with RVR, diffuse deep T-wave inversions (figure 4) | Sinus rhythm with diffuse ST-T changes (figure 5) | Sinus rhythm with deep T-wave inversions (figure 6) | AF, with diffuse ST-T changes (figure 7) | Sinus tachycardia with PACs and T-wave inversions (figure 8) | Sinus tachycardia with diffuse ST-T changes (figure 9) |
| Hospital day TTE done | 1 | 4 | 3 | 7 | 2 | 20 | 3 |
| Ejection fraction | 15% | 53% | 45% | 20% | 30% | 40% | 45% |
| Variant of TC | Typical | Biventricular | Reverse | Typical | Global with apical cap sparing | Reverse | Typical |
| Hydroxychloroquine/azithromycin use | No | No | Yes | Yes | No | Yes | No |
| Length of hospital stay | 2 | 16 | 25 | 12 | 8 | 44 | 17 |
| ICU days | 2 | 10 | 24 | 0 | 4 | 39 | 15 |
| Complications | AKI, shock liver, AF RVR | AKI recovered | ARDS, chronic respiratory failure | ARDS Shock | Bilateral pleural effusion s/p thoracentesis, AKI, NSVT | Bilateral pneumothorax s/p chest tube placement, transient transaminitis | AKI, metabolic encephalopathy |
| Outcome | Death | SNF | LTAC | Death | Recovered cardiac function but died secondary to other complications of COVID-19 | Recovered cardiac function LTAC | Recovered cardiac function Death |
AF, atrial fibrillation; AKI, acute kidney injury; AMS, altered mental status; ARDS, acute respiratory distress syndrome; CAD, coronary artery disease; CPK, creatine phospho kinase; CRF, chronic renal failure; CRP, C reactive protein; CVA, cerebrovascular accident; DM, diabetes mellitus; DOE, dyspnoea on exertion; F, female; FEU, fibrinogen equivalent units; FiO2, fractional inspired oxygen; HFrEF, heart failure with reduced ejection fraction; HLD, hyperlipidaemia; HTN, hypertension; ICU, intensive care unit; LDH, lactate dehydrogenase; LTAC, long-term acute care; M, male; NSVT, non-sustained ventricular tachycardia; PAC, premature atrial contractions; PaO2, arterial oxygen pressure; RVR, rapid ventricular rate; SNF, skilled nursing facility; SOB, shortness of breath; s/p, status post; TC, Takotsubo cardiomyopathy; TTE, transthoracic echocardiogram.